Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc. (KPRX): 9 pipeline candidates · ~14 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.4 months
D/E 0.52 · 5% dilution
Lead: Phase 2
9 candidates
N/A
N/A
A transparent, data-derived signal for Kiora Pharmaceuticals Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$11.1M
Cash
$11.0M
Quarterly Burn
$3.2M
Runway
14.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| 100 μg kio-301 | Phase 2 |
| 50 μg kio-301 | Phase 2 |
| kio-101 | Phase 2 |
| kio-101 | Phase 2 |
| kio-104 | Phase 2 |
| kio-104 | Phase 2 |
| kio-201 | Phase 2 |
| kio-301 | Phase 2 |
| kio-301 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
18
Total value held
$21.8M
| Holder | Shares | Value |
|---|---|---|
| alliancebernstein l.p. | 473,000 | $16.9M |
| wealth enhancement advisory services, llc | 106,690 | $3.8M |
| jane street group, llc | 13,440 | $475K |
| adar1 capital management, llc | 167,941 | $324K |
| citadel advisors llc | 49,533 | $96K |
| geode capital management, llc | 47,850 | $92K |
| vanguard capital management llc | 39,722 | $77K |
| xtx topco ltd | 14,719 | $28K |
| vanguard fiduciary trust co | 13,030 | $25K |
| two sigma securities, llc | 12,019 | $23K |
Showing top 10 of 18 institutional holders of Kiora Pharmaceuticals Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Kiora Pharmaceuticals Inc.'s pipeline?
Kiora Pharmaceuticals Inc. (KPRX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kiora Pharmaceuticals Inc.'s lead drug candidate?
Kiora Pharmaceuticals Inc.'s most advanced tracked candidate is 100 μg kio-301 (Phase 2) for Retinitis Pigmentosa.
What is Kiora Pharmaceuticals Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kiora Pharmaceuticals Inc. has approximately 14.4 months of cash runway.
What is Kiora Pharmaceuticals Inc.'s market capitalization?
Kiora Pharmaceuticals Inc.'s market capitalization is approximately $11.1M.
Who is the CEO of Kiora Pharmaceuticals Inc.?
Dr. Brian M. Strem Ph.D. is the chief executive officer of Kiora Pharmaceuticals Inc. (KPRX).
Get the full picture on Kiora Pharmaceuticals Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.